Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 51 results for age-related macular degeneration

  1. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

  2. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

  3. Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

    Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.

  4. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

  5. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

  6. Radiotherapy for age-related macular degeneration (HTG24)

    Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.

  7. Miniature lens system implantation for advanced age-related macular degeneration

    Topic prioritisation

  8. Transpupillary thermotherapy for age-related macular degeneration (HTG31)

    Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.

  9. Miniature lens system implantation for advanced age-related macular degeneration

    Awaiting development Reference number: GID-HTG10468 Expected publication date: TBC

  10. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

  11. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

  12. Digital technologies to support monitoring of vision change at home for people with age-related macular degeneration: early use assessment

    In development Reference number: GID-HTE10073 Expected publication date:  15 September 2026

  13. Limited macular translocation for wet age-related macular degeneration (HTG215)

    Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

  14. Miniature lens system implantation for advanced age-related macular degeneration (HTG418)

    Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.

  15. Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)

    Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.